Should I Buy ASPI? ASPI 2026 Analysis

Should You Buy ASP Isotopes Inc (ASPI) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Buy

Latest Price

6.340

1 Day change

-12.43%

52 Week Range

14.490

Analysis Updated At

2026/01/29

ASP Isotopes Inc (ASPI) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company has strong growth potential driven by its advanced isotope-enrichment technology, pending acquisition of Renergen, and planned spinout of its quantum laser enrichment technology. Despite recent price declines, the long-term catalysts and analyst optimism make it a favorable investment opportunity.

Technical Analysis

The MACD is positive and contracting, indicating a potential reversal or stabilization. RSI is neutral at 43.258, showing no overbought or oversold conditions. The stock is trading near its support level (S1: 6.952), which could act as a buying opportunity. However, the price is below the pivot point of 7.67, suggesting caution in the short term.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

ASP Isotopes has developed advanced isotope-enrichment technology, positioning itself as a leader in high-value nuclear fuel and medical isotopes.
The pending acquisition of Renergen could provide access to the world's largest high-concentration helium deposit.
The company has reported a 60% increase in gas processing capacity and an 80% drilling success rate, enhancing commercialization potential.
Analyst coverage initiated with an Overweight rating and a $13 price target, indicating significant upside potential.

Neutral/Negative Catalysts

Recent price decline of -8.82% in regular trading and -1.39% in pre-market trading, which may deter short-term investors.
Investigation by Halper Sadeh LLC into potential breaches of fiduciary duties by directors, which could impact corporate governance.
Gross margin dropped significantly by -68% YoY, indicating cost pressures.

Financial Performance

In Q3 2025, revenue increased by 349.53% YoY to $4,889,526, showcasing strong growth. Net income improved by 77.05% YoY but remains negative at -$12,874,007. EPS improved by 25% YoY to -0.15. However, gross margin dropped to 8.65%, down -68% YoY, highlighting cost challenges.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Cantor Fitzgerald initiated coverage with an Overweight rating and a $13 price target, citing the company's advanced technology and potential value creation from acquisitions and spinouts. This suggests strong analyst confidence in the company's long-term prospects.

3 Analyst Rating

Wall Street analysts forecast ASPI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ASPI is 13 USD with a low forecast of 11 USD and a high forecast of 15 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 7.240

Low

Averages

High

Current: 7.240

Low

Averages

High

Cantor Fitzgerald

Derek Soderberg

Overweight

initiated

$13

AI Analysis

2025-12-04

Reason

Cantor Fitzgerald

Derek Soderberg

Price Target

$13

AI Analysis

2025-12-04

initiated

Overweight

Reason

Cantor Fitzgerald analyst Derek Soderberg initiated coverage of ASP Isotopes (ASPI) with an Overweight rating and $13 price target. ASP Isotopes has developed advanced isotope-enrichment technology that produces high-value nuclear fuel, medical isotopes, and silicon-28, and currently stands as the sole commercial-scale provider of certain isotopes, the analyst tells investors in a research note. The pending acquisition of Renergen (RGNNF) could give ASPI control of the world's largest high-concentration helium deposit, while the planned spinout of its quantum laser enrichment technology represents a near-term value-creation opportunity, Cantor says.

Cantor Fitzgerald

Derek Soderberg

initiated

$13

2025-12-04

Reason

Cantor Fitzgerald

Derek Soderberg

Price Target

$13

2025-12-04

initiated

Reason

Cantor Fitzgerald analyst Derek Soderberg initiated coverage of ASP Isotopes with an Overweight rating and $13 price target.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ASPI

Unlock Now

ASPI Should I Buy

ASPI Should I Buy

Should You Buy ASP Isotopes Inc (ASPI) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch